ProfileGDS5678 / 1454852_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 88% 89% 90% 88% 89% 89% 89% 89% 89% 89% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8448688
GSM967853U87-EV human glioblastoma xenograft - Control 26.7201687
GSM967854U87-EV human glioblastoma xenograft - Control 36.9533788
GSM967855U87-EV human glioblastoma xenograft - Control 47.2508489
GSM967856U87-EV human glioblastoma xenograft - Control 57.2728990
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6152388
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7519189
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0686189
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0247189
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0593689
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0393389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0112989
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.102289
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0892989